GPRO Related Analyst Ratings
-
Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
-
William Blair Upgrades Gen-Probe (GPRO) to Outperform
-
Oppenheimer Upgrades Gen-Probe (GPRO) to Outperform
-
Leerink Swann Downgrades Gen-Probe (GPRO) to Market Perform
-
William Blair Downgrades Gen-Probe (GPRO) to Market Perform
-
Baird Downgrades Gen-Probe (GPRO) to Neutral
-
Maxim Initiates Coverage on Gen-Probe (GPRO) with a Buy
-
ThinkEquity Initiates Coverage on Gen-Probe (GPRO) with a Buy
-
Bank of America Resumes Coverage on Gen-Probe (GPRO) with a Buy
-
Matrix Lighthouse Changes 12/10
-
Morgan Stanley Downgrades Gen-Probe (GPRO) to Equalweight
-
JPMorgan Selects 26 Small, Mid-Cap Stocks That Can Outperform
-
Cowen & Co Downgrades Gen Probe (GPRO) to Neutral
-
William Blair Initiates Coverage on Gen-Probe (GPRO) with an Outperform
-
Oppenheimer Initiates Coverage on Gen-Probe (GPRO) with a Market Perform
-
Matrix USA Rating Changes 5/20
-
RBC Capital Starts Gen-Probe (GPRO) at Outperform
-
Deutsche Bank Starts Gen-Probe Inc. (GPRO) at Buy with $78 PT
-
Piper Jaffray Raises Their Price Target on Gen-Probe (GPRO) to $68
-
Morgan Stanley Starts Gen Probe (GPRO) at Overweight
-
Lehman Bros. Initiates Coverage on Gen-Probe (GPRO) with an Overweight
-
Robert W Baird upgrades Gen-Probe (GPRO) to Outperform
-
Piper Jaffray Comments on Speculation NVS/CHIR Could Sell Blood Testing Business to GPRO
-
Baird downgrades GPRO to Neutral
-
Banc of America Starts GPRO at Buy
-
Baird upgrades GPRO to Outperform
-
Merrill Lynch Upgraded GPRO
-
Baird downgrades GPRO to Neutral
-
J.P. Morgan Upgrades Gen-Probe
Back to GPRO Stock Lookup
